Adult T-cell leukemia/lymphoma in a Peruvian hospital in human T-lymphotropic virus type 1 (HTLV-1) positive patients.
Milton José Max Rodríguez-ZúñigaFlorencio Cortez-FrancoEberth Qujiano-GomeroPublished in: International journal of dermatology (2017)
ATLL is developed after years of HTLV-1 carrier status; therefore, physicians should know the principal clinical and laboratory findings in order to make prompt diagnosis. Prognosis is still poor in aggressive and indolent variants, with survival rates from months to a few years. Treatment based on chemotherapy, antiretroviral, and allogeneic stem cell transplantation are improving survival rates but with limited results.
Keyphrases
- stem cell transplantation
- high dose
- end stage renal disease
- newly diagnosed
- bone marrow
- ejection fraction
- endothelial cells
- primary care
- chronic kidney disease
- hiv infected
- human immunodeficiency virus
- emergency department
- healthcare
- prognostic factors
- free survival
- diffuse large b cell lymphoma
- hiv positive
- gene expression
- dna methylation
- copy number
- low dose
- hiv aids
- adverse drug
- replacement therapy
- hiv infected patients